Compare AbbVie Inc (ABBV) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while Consumer Discretionary Select Sector SPDR Fund trades at $115.27. The key difference: AbbVie Inc pays a 2.72% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and AbbVie Inc is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ABBV | XLY | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $124.52 |
52-Week Low | $184.85 | $105.64 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
XLY trades at $118.01, up 0.77% today, with a bullish technical signal from moving averages and support at $117. Analyst consensus is unanimously positive with 100% buy ratings, though key valuation metrics remain unavailable. Recent news highlights consumer discretionary sector strength during holiday spending periods.
The ETF's outlook remains favorable given strong technical momentum and positive analyst sentiment, though investors should monitor consumer spending trends and inflation impacts. Key risks include macroeconomic pressures on discretionary spending and sector competition from alternative funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
